Why Is BAUSCH HEALTH COS IN (BHC) Stock Up Today?

Bausch Health Companies Inc (BHC) shares surged 28.76% to close at $8.91. The sharp gain followed the release of third-quarter 2026 results, which featured adjusted EBITDA topping $1 billion and a raised full-year revenue outlook.

What Happened

The company reported strong third-quarter performance, with adjusted EBITDA exceeding $1 billion. Management outlined a 2026 revenue guidance range of $5.525 billion to $5.625 billion, signaling confidence in future growth despite flagged headwinds for the drug Xifaxan in the fourth quarter. Analysts responded positively to the earnings beat. RBC Capital maintained a Sector Perform rating while raising its price target to $10.00. Jefferies also raised its price target to $8.00 from $6.50, citing the revenue beat. The stock printed 35 fresh 52-week highs on October 29, 2026.

What The Data Shows

Bausch Health has a market capitalization of $2.4 billion and remains unprofitable, with a trailing twelve-month EPS of negative $2.95. Revenue grew 10.1% over the trailing twelve months, though the net margin stands at negative 10.1%. The stock exhibits low volatility with a beta of 0.37. Over the last eight sessions, the stock moved up 31.6%, rising from $6.42 to $8.45 before the current session. The 52-week range is $4.33 to $8.00, meaning the current price of $8.91 is above the previous high. Insider activity has been minimal, with one sale totaling $259,000 by Lenar Aimee J., President of US Pharma, on August 19, 2026. There have been no insider buys in the last 90 days.

What To Watch

Investors will monitor the company's ability to sustain the raised revenue guidance through the fourth quarter, particularly as it navigates the anticipated headwinds for Xifaxan.